Author:
Kairuz Dylan,Singh Prashika,Smith Tiffany,Arbuthnot Patrick,Ely Abdullah,Bloom Kristie
Publisher
Springer International Publishing
Reference153 articles.
1. Adams D, Gonzalez-Duarte A, O’Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11–21
2. Adibzadeh S, Fardaei M, Takhshid MA et al (2019) Enhancing stability of destabilized green fluorescent protein using chimeric mRNA containing human beta-globin 5′ and 3′ untranslated regions. Avicenna J Med Biotechnol 11:112–117
3. Akinc A, Querbes W, De S et al (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18:1357–1364
4. Alexopoulou L, Holt AC, Medzhitov R et al (2001) Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413:732–738
5. Anderson BR, Muramatsu H, Jha BK et al (2011) Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res 39:9329–9338